HIV type 1 fitness evolution in antiretroviral-experienced patients with sustained CD4+ T cell counts but persistent virologic failure

Clinical Infectious Diseases

Volumn 41, Issue 5, 2005, Pages 729-737

  Prado, Julia G ^a   Parkin, Neil T ^b   Clotet, Bonaventura ^a   Ruiz, Lidia ^a   Martinez Picado, Javier ^a,c  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b MONOGRAM BIOSCIENCES   (United States)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIGEN P24; ANTIRETROVIRUS AGENT; DIDANOSINE; GAG PROTEIN; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CASE REPORT; CONTROLLED STUDY; DRUG SENSITIVITY; EVOLUTION; FITNESS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PLASMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS FITNESS; VIRUS INFECTIVITY; VIRUS LOAD; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, MULTIPLE, VIRAL; EVOLUTION, MOLECULAR; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; PHENOTYPE; RNA, VIRAL; TIME FACTORS;

EID: 23844556486     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/432619     Document Type: Article

References (37)

1. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-9.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
3. Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003; 37:113-28.
4. Richman DD. HIV chemotherapy. Nature 2001; 410:995-1001.
5. Menendez-Arias L, Martinez MA, Quinones-Mateu ME, Martinez-Picado J. Fitness variations and their impact on the evolution of antiretroviral drug resistance. Curr Drug Targets Infect Disord 2003; 3:355-71.
6. Nijhuis M, Decks S, Boucher C. Implications of antiretroviral resistance on viral fitness. Curr Opin Infect Dis 2001; 14:23-8.
7. Quinones-Mateu ME, Arts EJ. Fitness of drug resistant HIV-1: methodology and clinical implications. Drug Resist Updat 2002; 5:224-33.
8. Nijhuis M, Schuurman R, de Jong D, et al. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. Aids 1999; 13:2349-59.
9. Martinez-Picado J, Savara AV, Shi L, Sutton L, D'Aquila RT. Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants. Virology 2000; 275:318-22.
10. Prado JG, Franco S, Matamoros T, et al. Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215. Virology 2004; 326:103-12.
11. Prado JG, Wrin T, Beauchaine J, et al. Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. Aids 2002; 16:1009-17.
12. Haubrich R, Wrin T, Hellmann N, et al. Replication capacity as a predictor of immunological and virological benefit despite virological failure of an antiretroviral treatment. Antivir Ther 2002; 7(Suppl):S101.
13. Martinez-Picado J, Sutton L, De Pasquale MP, Savara AV, D'Aquila RT. Human immunodeficiency virus type 1 cloning vectors for antiretroviral resistance testing. J Clin Microbiol 1999; 37:2943-51.
14. Petropoulos CJ, Parkin NT, Limoli KL, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000; 44:920-8.
15. Decks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344:472-80.
16. Gamarnik A, Wrin T, Ziermann R, et al. Drug resistance is associated with impaired protease and reverse transcriptase function and reduced replication capacity: characterization of recombinant viruses derived from 200 HIV-1 infected patients. Antivir Ther 2000;5(Suppl):S92.
17. Nicastri E, Sarmati L, d'Ettorre G, et al. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy. J Med Virol 2003; 69:1-6.
18. Bleiber G, Munoz M, Ciuffi A, Meylan P, Telenti A. Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1. J Virol 2001; 75:3291-300.
19. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2004. Top HIV Med 2004; 12:119-24.
20. Resch W, Ziermann R, Parkin N, Gamarnik A, Swanstrom R. Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the gag polyprotein precursor aberrantly. J Virol 2002; 76:8659-66.
21. + T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection. J Infect Dis 2004; 190:251-6.
22. Wei X, Liang C, Gotte M, Wainberg MA. The M184V mutation in HIV-1 reverse transcriptase reduces the restoration of wild-type replication by attenuated viruses. AIDS 2002; 16:2391-8.
23. Martinez-Picado J, Morales-Lopetegi K, Wrin T, et al. Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions. Aids 2002; 16:895-9.
24. Parkin N, Bates M, Chappey C, Limoli K, Petropoulus CJ. Relationship between low replication capacity and protease inhibitor hypersusceptibility in >3000 clinical samples lacking protease inhibitor resistance mutations. Antivir Ther 2004;9(Suppl):S63.
25. Simon V, Padte N, Murray D, et al. Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection. J Virol 2003; 77:7736-45.
26. Yuste E, Sanchez-Palomino S, Casado C, Domingo E, Lopez-Galindez C. Drastic fitness loss in human immunodeficiency virus type 1 upon serial bottleneck events. J Virol 1999; 73:2745-51.
27. Sierra S, Davila M, Lowenstein PR, Domingo E. Response of foot-and-mouth disease virus to increased mutagenesis: influence of viral load and fitness in loss of infectivity. J Virol 2000; 74:8316-23.
28. Peters S, Munoz M, Yerly S, et al. Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein. J Virol 2001; 75:9644-53.
29. Gallego O, de Mendoza C, Corral A, Soriano V. Changes in the human immunodeficiency virus p7-p1-p6 gag gene in drug-naive and pre-treated patients. J Clin Microbiol 2003; 41:1245-7.
30. Cote HC, Brumme ZL, Harrigan PR. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir. J Virol 2001; 75:589-94.
31. Carrillo A, Stewart KD, Sham HL, et al. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J Virol 1998; 72:7532-41.
32. Mammano F, Petit C, Clavel F. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J Virol 1998; 72:7632-7.
33. Maguire MF, Guinea R, Griffin P, et al. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J Virol 2002; 76:7398-406.
34. Myint L, Matsuda M, Matsuda Z, et al. Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48:444-52.
35. Gatanaga H, Suzuki Y, Tsang H, et al. Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors. J Biol Chem 2002; 277:5952-61.
36. Bally F, Martinez R, Peters S, Sudre P, Telenti A. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors. AIDS Res Hum Retroviruses 2000; 16:1209-13.
37. Tamiya S, Mardy S, Kavlick MF, Yoshimura K, Mistuya H. Amino acid insertions near gag cleavage sites restore the otherwise compromised replication of human immunodeficiency virus type 1 variants resistant to protease inhibitors. J Virol 2004; 78:12030-40.